Haemonetics handed $15M in patent ruling
Braintree-based Haemonetics Corp., a provider of blood management products, has won a $15.7 million settlement for alleged patent infringement.
This week, a federal court ordered Fenwal Inc., a transfusion products provider based in Illinois, to make the payment to Haemonetics (NYSE: HAE). The judgment followed seven days of trial and two days of deliberation by the jury, stated law firm Sherin and Lodgen LLP, which represented Haemonetics. The trial was held in the U.S. District Court for Massachusetts. Fenwal’s blood collecting device was found to be in violation of Haemonetics’ patent for an automated blood collection system.
Thursday, February 5, 2009
The Journal of New England Technology